Hemerion is participating for the first time in the American Association of Neurological Surgeons (AANS) Annual Meeting, held in San Antonio, Texas, from May 1 to 4, 2026.
This major event marks a continued expansion of our international clinical network. Our ultimate goal is to launch a pivotal trial for the Pentalafen/Heliance therapy, which represents the final step before we submit a marketing authorization application in the U.S.
The AANS Annual Meeting is one of the most anticipated highlights of innovation in neurosurgery in the United States and around the world, with nearly 5,000 attendees, including many of the sector’s key opinion leaders.
Expanding our international clinical network
Hemerion’s team will attend the AANS Annual Scientific Meeting to share its most recent clinical findings and to facilitate the establishment of operational future clinical trial sites.
Hemerion is currently finalizing its third Phase 1/2 clinical trial and, in early 2026, received approval from the Food and Drug Administration (FDA) to initiate an Accelerated Approval process.
The U.S. health agency has also validated the clinical development strategy proposed by Hemerion, which aims for a U.S. marketing authorization application by 2029.
These significant developments place the Pentalafen/Heliance therapy in an optimal position for the initiation of its pivotal clinical trial, which represents the final stage before the submission for marketing authorization.
Demonstrating the Technology’s Advantages
Our team’s participation in this event also provides an opportunity to offer demonstrations of the Heliance illumination platform, to explain the mechanism of action of its technology, to demonstrate its value in the surgical treatment of brain tumors, and to concretely illustrate its ease of use in the operating room.
This event will allow our team to showcase the Heliance illumination platform through live demonstrations. We will explain its mechanism of action, illustrate its value in the surgical treatment of brain tumors, and demonstrate its straightforward implementation in the operating room.